Sai Life Sciences
765.25
+37.20(+5.11%)
Market Cap₹15,150.70 Cr
PE Ratio89.47
IndustryHealthcare
Company Performance:
1D+5.11%
1M+4.64%
6M+8.75%
1Y+0.08%
5Y+0.08%
View Company Insightsright
Latest news about Sai Life Sciences
TPG Offloads Rs 1,505 Crore Stake in Sai Life Sciences, Stock Rallies 5% 2 hours ago Today
Private equity firm TPG sold over 2 crore shares of Sai Life Sciences at Rs 722.00 per share, totaling approximately Rs 1,505.00 crore. Key buyers included Norges Bank and Indian mutual funds such as Nippon India, Invesco, and Aditya Birla Sun Life. The stock rallied 5% following the transaction, closing at Rs 765.85 on the BSE. Sai Life Sciences is a contract research, development, and manufacturing organization serving the pharmaceutical industry.
SAI Life Sciences Expands Capacity with Bidar Unit IV Phase Two Launch 11 hours ago Today
Sai Life Sciences: Major Block Deal Sees 10% Equity Change Hands 13 hours ago Today
TPG Asia to Offload 6% Stake in Sai Life Sciences for ₹887.5 Crore 1 day ago Yesterday
Sai Life Sciences Sets Ambitious Growth Targets, Eyes Margin Expansion May 14, 2025
More news about Sai Life Sciences
04Apr 25
Sai Life Sciences Expands Research Capabilities with New Peptide Research Center in India
Sai Life Sciences has established a new Peptide Research Center at its R&D Campus in Hyderabad, India. The facility features state-of-the-art technology for complex peptide synthesis and conjugation, including automation and robotics. This expansion aims to meet the growing demand for peptide-based therapeutics and reinforces the company's position in advancing next-generation drugs. The center will offer specialized services in peptide synthesis, discovery, and advanced modalities, integrated with Sai Life Sciences' existing end-to-end discovery services.
03Apr 25
Sai Life Sciences Expands Capabilities with New Peptide Research Center in India
Sai Life Sciences has established a new Peptide Research Center at its R&D Campus in Hyderabad, India. The state-of-the-art facility integrates automation, advanced liquid handling, robotics, and high-throughput systems to enhance peptide research and development. It offers specialized services in peptide synthesis, discovery, and advanced modalities, supporting innovator pharma and biotech companies. The center is integrated with Sai Life Sciences' existing end-to-end discovery services, aiming to accelerate timelines for peptide-based drug development.
Sai Life Sciences
765.25
+37.20
(+5.11%)
1 Year Returns:+0.08%
Industry Peers
Sun Pharmaceutical
1,665.10
(+1.06%)
Divis Laboratories
6,592.00
(+1.52%)
Cipla
1,499.70
(+1.06%)
Dr Reddys Laboratories
1,325.30
(-0.06%)
Torrent Pharmaceuticals
3,167.20
(+0.10%)
Mankind Pharma
2,288.80
(-1.57%)
Zydus Life Science
957.10
(+0.74%)
Lupin
1,948.00
(+0.84%)
Abbott
31,620.00
(+1.90%)
Aurobindo Pharma
1,097.20
(+1.36%)